Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2633035 | 0.95 | AR (0.63) | ARNR3C1HDAC1 | |
| SCHEMBL15468236 | 0.90 | AR (0.59) | ARNR3C1HDAC1 | |
| SCHEMBL13973946 | 0.89 | AR (0.51) | ARNR3C1HDAC1 | |
| SCHEMBL30184873 | 0.88 | AR (0.76) | ARNR3C1HDAC1 | |
| SCHEMBL547082 | 0.88 | AR (0.76) | ARNR3C1HDAC1 | |
| SCHEMBL11892452 | 0.86 | AR (0.77) | AR | |
| SCHEMBL10073489 | 0.86 | AR (0.64) | ARNR3C1 | |
| SCHEMBL1715961 | 0.85 | AR (0.64) | ARNR3C1HDAC1 | |
| SCHEMBL29508773 | 0.85 | AR (0.64) | ARNR3C1HDAC1 | |
| SCHEMBL1715648 | 0.85 | AR (0.75) | ARNR3C1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110594-B2 | Diarylthiohydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | disclosed |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | AR, LHCGR, KLK3 | AR 1/4885NR3C1 37/4885HDAC1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.